Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice

Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice - Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030109

Enrollment

Registered

2017-12-01

Start date

2014-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Patients receive IFX (3 mg/kg) at 0, 2, 6, 14 and 22 weeks. The dose escalation of IFX to 6 mg/kg was allowed after 14 weeks if DAS28-ESR remission had not been achieved according to medicinal applica

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients who had not achieved low disease activity (LDA) status on the DAS28-ESR LDA despite undergoing bDMARD therapy.

Exclusion criteria

Exclusion criteria: non

Design outcomes

Primary

Measure	Time frame
The primary endpoint in this study was the rate of achievement of LDA or remission at week 22after the introduction of infliximab. The adverse events during the observation period.	—

Countries

Japan

Contacts

Public ContactMasataka Umeda

Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Scie Department of Rheumatology

umeda@nagasaki-u.ac.jp095-819-7262

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026